Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Clinical evidence

CDX0159-06

95 evidence topics · 19 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Treatment discontinuations through Week 52 by randomized group
Reason75 mg every 4 weeks, then 150 or 300 mg150 mg every 4 weeks300 mg every 8 weeksPlacebo, then 150 or 300 mg
Group size“(n=53)”“(n=52)”“(n=52)”“(n=51)”
Discontinued treatment, n (%)“13 (25%)”“13 (25%)”“13 (25%)”“8 (16%)”
Adverse event“7 (13%)”“4 (8%)”“7 (13%)”“2 (4%)”
Patient decision“1 (2%)”“3 (6%)”“1 (2%)”“3 (6%)”
Non-compliance“2 (4%)”“1 (2%)”“1 (2%)”“2 (4%)”
Lack of clinical response“1 (2%)”“0”“2 (4%)”“1 (2%)”
Other“2 (4%)”“5 (10%)”“2 (4%)”“0”
Baseline characteristics
Demographics and baseline disease characteristics by randomized group
Characteristic75 mg every 4 weeks (n = 53)150 mg every 4 weeks (n = 52)300 mg every 8 weeks (n = 51)Placebo (n = 51)
Age (years), median (range)“42.0 (18-69)”“44.5 (21-81)”“49.0 (20-80)”“43.0 (20-76)”
Female sex, no. (%)“40 (75.5)”“39 (75.0)”“41 (80.4)”“36 (70.6)”
Weight (kg), mean (SD)“77.49 (20.442)”“80.86 (21.354)”“85.73 (24.852)”“83.81 (19.866)”
UAS7 score, mean (SD)“30.30 (8.057)”“30.75 (7.657)”“31.33 (6.939)”“30.09 (8.057)”
UAS7, severe disease (UAS7 ≥ 28), no. (%)“34 (64.2%)”“36 (69.2%)”“39 (76.5%)”“33 (64.7%)”
ISS7 score, mean (SD)“15.44 (4.053)”“15.70 (4.004)”“16.42 (3.658)”“15.61 (3.783)”
HSS7 score, mean (SD)“14.86 (4.588)”“15.05 (5.045)”“14.92 (4.387)”“14.47 (4.842)”
UCT score, mean (SD)“3.67 (2.826)”“3.67 (2.503)”“2.96 (2.630)”“3.38 (2.472)”
Angioedema at baseline (AAS7 > 0), no. (%)“40 (75.5%)”“35 (67.3%)”“42 (82.4%)”“32 (62.7%)”
Duration of CSU (years), mean (SD)“5.44 (5.352)”“5.47 (6.538)”“6.28 (6.554)”“5.27 (6.565)”
Previous experience with omalizumab, no. (%)“11 (20.8)”“11 (21.2)”“11 (21.6)”“8 (15.7)”
Baseline IgE (IU/mL), median (IQR)“81 (27.0-271.0)”“60 (13.0-135.0)”“91.5 (35.5-218.0)”“101.5 (25.0-237.8)”
Dermatology Life Quality Index, mean (SD)“15.88 (7.596)”“15.65 (7.634)”“17.37 (7.534)”“16.98 (6.556)”
Baseline tryptase (ng/mL), median (IQR)“5.25 (3.43-6.80)”“5.40 (4.30-6.90)”“4.80 (3.85-6.55)”“4.40 (3.25-6.55)”
Efficacy results
Week 12 efficacy endpoints by randomized group
Endpoint at Week 1275 mg every 4 weeks (n = 53)150 mg every 4 weeks (n = 52)300 mg every 8 weeks (n = 51)Placebo (n = 51)
UAS7 LS mean change from baseline (SE)“−17.06 (1.493)”“−23.02 (1.416)”“−23.87 (1.479)”“−10.47 (1.462)”
UAS7 treatment difference vs placebo (95% CI)“−6.60 (−10.71, −2.49)”“−12.55 (−16.56, −8.55)”“−13.41 (−17.47, −9.34)”Not applicable
ISS7 LS mean change from baseline (SE)“−8.62 (0.794)”“−11.68 (0.766)”“−11.79 (0.788)”“−5.47 (0.784)”
ISS7 treatment difference vs placebo (95% CI)“−3.16 (−5.41, −0.91)”“−6.21 (−8.38, −4.04)”“−6.32 (−8.50, −4.13)”Not applicable
HSS7 LS mean change from baseline (SE)“−8.25 (0.747)”“−11.19 (0.750)”“−12.19 (0.745)”“−4.95 (0.772)”
HSS7 treatment difference vs placebo (95% CI)“−3.31 (−5.40, −1.22)”“−6.24 (−8.33, −4.16)”“−7.24 (−9.36, −5.12)”Not applicable
AAS7 LS mean change from baseline (SE)“−24.10 (2.831)”“−27.99 (2.815)”“−29.95 (2.843)”“−12.56 (3.056)”
AAS7 treatment difference vs placebo (95% CI)“−11.55 (−20.04, −3.05)”“−15.43 (−23.52, −7.34)”“−17.39 (−25.49, −9.30)”Not applicable
Well-controlled disease (UAS7 ≤ 6) (%)“41.7”“59.6”“62.5”“12.8”
UAS7 ≤ 6 difference in proportions vs placebo (95% CI)“0.29 (0.12, 0.46)”“0.47 (0.3, 0.64)”“0.50 (0.33, 0.66)”Not applicable
Complete control (UAS7 = 0) (%)“22.9”“51.1”“37.5”“6.4”
UAS7 = 0 difference in proportions vs placebo (95% CI)“0.17 (0.03, 0.3)”“0.45 (0.29, 0.61)”“0.31 (0.16, 0.46)”Not applicable
CSU-free status (ISS7 = 0, HSS7 = 0, and AAS7 = 0) (%)“19.2”“50.0”“33.3”“5.9”
Week 52 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) after re-randomization at Week 16
GroupUAS7 ≤ 6 at Week 12 (%)UAS7 ≤ 6 at Week 52 (%)UAS7 = 0 at Week 12 (%)UAS7 = 0 at Week 52 (%)
75 mg every 4 weeks, then 150 or 300 mg“41.7”“67.4”“22.9”“53.5”
150 mg every 4 weeks“59.6”“73.7”“51.1”“71.1”
300 mg every 8 weeks“62.5”“68.2”“37.5”“52.3”
Placebo, then 150 or 300 mg“12.8”“63.0”“6.4”“58.7”
Health-related quality of life and patient-reported outcomes
Safety results
Baseline through Week 12: adverse events, serious adverse events, and discontinuations
Event75 mg every 4 weeks (n = 53)150 mg every 4 weeks (n = 52)300 mg every 8 weeks (n = 51)Pooled barzolvolimab (n = 156)Placebo (n = 51)
Patients with ≥1 TEAE“28 (52.8)”“29 (55.8)”“31 (60.8)”“88 (56.4)”“14 (27.5)”
Patients with serious AE“0”“0”“1 (2.0)”“1 (0.6)”“0”
Discontinued study treatment due to TEAE“2 (3.8)”“1 (1.9)”“4 (7.8)”“7 (4.5)”“0”
Hair color changes“0”“5 (9.6)”“9 (17.6)”“14 (9.0)”“0”
Urticaria/CSU“8 (15.1)”“5 (9.6)”“3 (5.9)”“16 (10.3)”“5 (9.8)”
Neutropenia (neutropenia and neutrophil count decreased)“4 (7.6)”“3 (5.7)”“5 (9.8)”“12 (7.7)”“0”
Week 16 placebo-controlled period and Week 52 full treatment period: adverse events
Patients, n (%)Barzolvolimab, all doses, Weeks 0 to 16 (N= 156)Placebo, Weeks 0 to 16 (N= 51)Barzolvolimab, all doses, Weeks 0 to 52 (N= 156)Placebo then barzolvolimab, 36 weeks (N=48)
At least one AE“103 (66)”“20 (39)”“139 (89)”“32 (67)”
Treatment related SAEs“0”“0”“2 (1)”“0”
Hair color changes“22 (14)”“0”“40 (26)”“8 (17)”
Neutropenia / neutrophil count decreased“14 (9)”“0”“26 (17)”“2 (4)”
Urticaria“15 (10)”“5 (10)”“23 (15)”“3 (6)”
Skin hypopigmentation“2 (1)”“0”“21 (13)”“9 (19)”
Nasopharyngitis“6 (4)”“3 (6)”“15 (10)”“4 (8)”
Study limitations
Summary
  • Sample size: the study was sized at 168 participants (42 per group) for 80% power to detect a UAS7 difference of at least 9 points at week 12. Of 208 participants randomized, 207 were in the mITT and safety populations. Approximately 20% (n=41) had prior omalizumab, and the authors state of the omalizumab-refractory subgroup that “the number of patients in this subgroup was small”.
  • Duration of placebo control: the placebo-controlled treatment phase ran from baseline to week 16. At Week 16 the placebo and 75 mg groups were re-randomized 1:1 to 150 mg Q4W or 300 mg Q8W for 36 weeks, so every group received barzolvolimab from Week 16 to Week 52.
  • Peer-reviewed scope: the primary publication reports the primary analysis, conducted when all participants completed week 12. Week 52 results are from a congress presentation based on an interim data cut of July 31, 2024, and Week 76 results are from congress presentations and the Form 10-Q.
  • Multiplicity: the publication states “P values are nominal; only the primary end point P values were adjusted for multiplicity.”
  • Missing data: the week 12 primary analysis used analysis of covariance with multiple imputation, while the Week 76 and angioedema congress analyses are labeled modified intent to treat with observed data or as-observed. Overall, 189 participants (91.3%) completed 12 weeks of treatment. Through 52 weeks, 13 (25%) participants in each of the three barzolvolimab groups and 8 (16%) in the placebo-then-barzolvolimab group discontinued treatment, including 7 (13%), 4 (8%), 7 (13%), and 2 (4%) for adverse events.
  • Off-treatment and post hoc analyses: the last dose was at Week 48, followed by a 24-week off-treatment follow-up from Week 52 to Week 76. The off-treatment efficacy analysis was post hoc and limited to participants randomized to 150 mg Q4W or 300 mg Q8W who completed 52 weeks with UAS7 ≤ 6 at Week 52 (n = 55), of whom 48 had a reported UAS7 at Week 76. The baseline serum tryptase analyses were exploratory and post hoc.
  • Baseline imbalance: the 300 mg group had more participants with higher body weights, more with severe CSU (UAS7 ≥ 28), and a higher percentage with angioedema (82%) than the lower-dose groups and the placebo group.
  • Regimens: the phase 2 groups received 150 mg every 4 weeks or 300 mg every 8 weeks for 52 weeks, with placebo injections at the intervening visits of the every-8-weeks group; the phase 3 regimens follow a 300 mg or 450 mg loading dose.
  • Counts that differ across documents: the study is described as conducted across 9 countries (Form 10-Q), at ~75 sites in 10 countries (52-week presentation), and at 56 locations (registry); the 300 mg every 8 weeks group is n = 51 in the primary publication and n=52 in the 52-week presentation.
  • Immunogenicity: no antidrug antibody results from this study were found.
  • Pigmentation analysis: the authors state “There were no protocol-defined standardization procedures for photography of hair or skin pigmentation changes” and that images were obtained from a subset of participants.